Trial Profile
Phase III trial of Melacine plus interferon alfa-2b versus interferon alfa-2b in patients with disseminated malignant melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Jul 2023
Price :
$35
*
At a glance
- Drugs Melanoma vaccine Melacine (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Corixa Corporation; GlaxoSmithKline; GSK; Ribi ImmunoChem Research
- 27 Dec 2007 New trial record.